CIELO WN43174

Recruiting

99 years and younger

All

Phase N/A

1 Location

Brief description of study

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER BASKET STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH ANTIN-METHYL-D-ASPARTIC ACID RECEPTOR (NMDAR) OR ANTILEUCINE-RICH GLIOMA-INACTIVATED 1 (LGI1) ENCEPHALITIS

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 13 Nov 2024. Study ID: 853981

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Brief description of study

Eligibility of study

Find a site

What happens next?

Interested in the study